Key Moments
- Regeneron Pharmaceuticals shares fell nearly 12% in premarket trading after its phase 3 fianlimab trial in metastatic melanoma did not meet its primary endpoint.
- The study showed a 5.1-month numerical increase in median progression-free survival for the high-dose fianlimab combination versus pembrolizumab monotherapy, but without statistical significance.
- Citi downgraded Regeneron to neutral with a reduced $700 price target, while BMO also cut its target by nearly 20% following the trial update.
Trial Results Undercut Market Expectations
Regeneron Pharmaceuticals saw its stock drop nearly 12% in premarket trading on Monday after the company announced that its phase 3 study of fianlimab in metastatic melanoma did not reach the main clinical goal.
According to the company, the trial failed to demonstrate statistical significance for the primary endpoint, which was improvement in progression-free survival.
Despite missing the primary objective, the study showed a numerical benefit: patients receiving the high-dose fianlimab combination experienced a 5.1-month increase in median progression-free survival compared with those treated with pembrolizumab monotherapy.
| Study Element | Outcome / Detail |
|---|---|
| Indication | Metastatic melanoma |
| Drug regimen | High-dose fianlimab combination vs pembrolizumab monotherapy |
| Primary endpoint | Improvement in progression-free survival |
| Primary endpoint result | No statistical significance achieved |
| Numerical outcome | 5.1-month improvement in median progression-free survival for high-dose fianlimab combination |
Ongoing Comparative Study Against Opdualag
Regeneron noted that development of fianlimab is continuing. A separate phase 3, head-to-head trial is underway, comparing the high-dose fianlimab combination directly with Opdualag (nivolumab and relatlimab-rmbw).
Analyst Reactions and Target Price Cuts
The setback in the phase 3 program prompted swift reactions from Wall Street. Citi downgraded Regeneron to neutral from buy and cut its price target on the stock to $700 from $900. Analyst Geoffrey Meacham attributed the change in rating and target to the disappointing phase 3 fianlimab data in metastatic melanoma and indicated that he expects continued pressure on the shares.
BMO also reduced its price target on Regeneron by nearly 20% after the trial update. Analyst Evan David Seigerman commented on the importance of the data release, stating, “This was to be the defining catalyst of 1H26, with share sentiment inextricably tied to this release,” he said.
TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover 
